APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Microbiome

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Selected research

Market Analysis & Forecast

Global Human Microbiome Market Analysis and Forecast 2026-2032

23 December 2025203 pages

Choose your research edition.

Industry ResearchHuman Microbiome Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Microbiome Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Human Microbiome Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Microbiome Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Microbiome Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).

These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.

An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.

Read the full market overview

At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.

Report Includes

This report presents an overview of global market for Human Microbiome, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Human Microbiome, also provides the revenue of main regions and countries. Of the upcoming market potential for Human Microbiome, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Human Microbiome revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Human Microbiome market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Human Microbiome revenue, projected growth trends, production technology, application and end-user industry.

Human Microbiome Segment by Company

Vedanta

Seres Therapeutics

Second Genome

Rebiotix

ActoGeniX

Enterome BioScience

AvidBiotics

4D Pharma Research Ltd

Enterologics

Metabogen

Metabiomics

Ritter Pharmaceuticals

Osel

Symberix

Miomics

Symbiotix Biotherapies

MicroBiome Therapeutics LLC

Human Microbiome Segment by Type

Gastrointestinal Tract Human Micobiome

Urogenital Tract Human Micobiome

Others

Human Microbiome Segment by Application

Treatment

Diagnosis

Human Microbiome Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Microbiome market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Microbiome and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Microbiome.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Human Microbiome in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Human Microbiome company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Microbiome revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Human Microbiome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Gastrointestinal Tract Human Micobiome Major Player Table 3. Urogenital Tract Human Micobiome Major Player Table 4. Others Major Player Table 5. Global Human Microbiome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Treatment Major Player Table 7. Diagnosis Major Player Table 8. Human Microbiome Industry Trends Table 9. Human Microbiome Industry Drivers Table 10. Human Microbiome Industry Opportunities and Challenges Table 11. Human Microbiome Industry Restraints Table 12. Global Human Microbiome Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Human Microbiome Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Human Microbiome Market Share by Region (2021-2026) Table 15. Global Human Microbiome Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Human Microbiome Market Share by Region (2027-2032) Table 17. Global Human Microbiome Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Human Microbiome Revenue Market Share by Players (2021-2026) Table 19. Global Human Microbiome Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Human Microbiome Key Players Headquarters & Area Served Table 21. Global Human Microbiome Players, Product Type & Application Table 22. Global Human Microbiome Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Human Microbiome by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Human Microbiome Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Human Microbiome Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Human Microbiome Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Human Microbiome Revenue Market Share by Type (2021-2026) Table 29. Global Human Microbiome Revenue Market Share by Type (2027-2032) Table 30. Global Human Microbiome Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Human Microbiome Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Human Microbiome Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Human Microbiome Revenue Market Share by Application (2021-2026) Table 34. Global Human Microbiome Revenue Market Share by Application (2027-2032) Table 35. Vedanta Company Information Table 36. Vedanta Business Overview Table 37. Vedanta Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Vedanta Human Microbiome Product Portfolio Table 39. Vedanta Recent Development Table 40. Seres Therapeutics Company Information Table 41. Seres Therapeutics Business Overview Table 42. Seres Therapeutics Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Seres Therapeutics Human Microbiome Product Portfolio Table 44. Seres Therapeutics Recent Development Table 45. Second Genome Company Information Table 46. Second Genome Business Overview Table 47. Second Genome Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Second Genome Human Microbiome Product Portfolio Table 49. Second Genome Recent Development Table 50. Rebiotix Company Information Table 51. Rebiotix Business Overview Table 52. Rebiotix Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Rebiotix Human Microbiome Product Portfolio Table 54. Rebiotix Recent Development Table 55. ActoGeniX Company Information Table 56. ActoGeniX Business Overview Table 57. ActoGeniX Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. ActoGeniX Human Microbiome Product Portfolio Table 59. ActoGeniX Recent Development Table 60. Enterome BioScience Company Information Table 61. Enterome BioScience Business Overview Table 62. Enterome BioScience Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Enterome BioScience Human Microbiome Product Portfolio Table 64. Enterome BioScience Recent Development Table 65. AvidBiotics Company Information Table 66. AvidBiotics Business Overview Table 67. AvidBiotics Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. AvidBiotics Human Microbiome Product Portfolio Table 69. AvidBiotics Recent Development Table 70. 4D Pharma Research Ltd Company Information Table 71. 4D Pharma Research Ltd Business Overview Table 72. 4D Pharma Research Ltd Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. 4D Pharma Research Ltd Human Microbiome Product Portfolio Table 74. 4D Pharma Research Ltd Recent Development Table 75. Enterologics Company Information Table 76. Enterologics Business Overview Table 77. Enterologics Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Enterologics Human Microbiome Product Portfolio Table 79. Enterologics Recent Development Table 80. Metabogen Company Information Table 81. Metabogen Business Overview Table 82. Metabogen Human Microbiome Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Metabogen Human Microbiome Product Portfolio Table 84. Metabogen Recent Development Table 85. Metabiomics Company Information Table 86. Metabiomics Business Overview Table 87. Metabiomics Human Microbiome Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Metabiomics Human Microbiome Product Portfolio Table 89. Metabiomics Recent Development Table 90. Ritter Pharmaceuticals Company Information Table 91. Ritter Pharmaceuticals Business Overview Table 92. Ritter Pharmaceuticals Human Microbiome Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Ritter Pharmaceuticals Human Microbiome Product Portfolio Table 94. Ritter Pharmaceuticals Recent Development Table 95. Osel Company Information Table 96. Osel Business Overview Table 97. Osel Human Microbiome Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Osel Human Microbiome Product Portfolio Table 99. Osel Recent Development Table 100. Symberix Company Information Table 101. Symberix Business Overview Table 102. Symberix Human Microbiome Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. Symberix Human Microbiome Product Portfolio Table 104. Symberix Recent Development Table 105. Miomics Company Information Table 106. Miomics Business Overview Table 107. Miomics Human Microbiome Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Miomics Human Microbiome Product Portfolio Table 109. Miomics Recent Development Table 110. Symbiotix Biotherapies Company Information Table 111. Symbiotix Biotherapies Business Overview Table 112. Symbiotix Biotherapies Human Microbiome Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 113. Symbiotix Biotherapies Human Microbiome Product Portfolio Table 114. Symbiotix Biotherapies Recent Development Table 115. MicroBiome Therapeutics LLC Company Information Table 116. MicroBiome Therapeutics LLC Business Overview Table 117. MicroBiome Therapeutics LLC Human Microbiome Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 118. MicroBiome Therapeutics LLC Human Microbiome Product Portfolio Table 119. MicroBiome Therapeutics LLC Recent Development Table 120. North America Human Microbiome Revenue by Type (2021-2026) & (US$ Million) Table 121. North America Human Microbiome Revenue by Type (2027-2032) & (US$ Million) Table 122. North America Human Microbiome Revenue by Application (2021-2026) & (US$ Million) Table 123. North America Human Microbiome Revenue by Application (2027-2032) & (US$ Million) Table 124. North America Human Microbiome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. North America Human Microbiome Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Human Microbiome Revenue by Country (US$ Million) & (2027-2032) Table 127. Europe Human Microbiome Revenue by Type (2021-2026) & (US$ Million) Table 128. Europe Human Microbiome Revenue by Type (2027-2032) & (US$ Million) Table 129. Europe Human Microbiome Revenue by Application (2021-2026) & (US$ Million) Table 130. Europe Human Microbiome Revenue by Application (2027-2032) & (US$ Million) Table 131. Europe Human Microbiome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Europe Human Microbiome Revenue by Country (2021-2026) & (US$ Million) Table 133. Europe Human Microbiome Revenue by Country (US$ Million) & (2027-2032) Table 134. China Human Microbiome Revenue by Type (2021-2026) & (US$ Million) Table 135. China Human Microbiome Revenue by Type (2027-2032) & (US$ Million) Table 136. China Human Microbiome Revenue by Application (2021-2026) & (US$ Million) Table 137. China Human Microbiome Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Human Microbiome Revenue by Type (2021-2026) & (US$ Million) Table 139. Asia Human Microbiome Revenue by Type (2027-2032) & (US$ Million) Table 140. Asia Human Microbiome Revenue by Application (2021-2026) & (US$ Million) Table 141. Asia Human Microbiome Revenue by Application (2027-2032) & (US$ Million) Table 142. Asia Human Microbiome Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Asia Human Microbiome Revenue by Region (US$ Million) & (2021-2026) Table 144. Asia Human Microbiome Revenue by Region (US$ Million) & (2027-2032) Table 145. SAMEA Human Microbiome Revenue by Type (2021-2026) & (US$ Million) Table 146. SAMEA Human Microbiome Revenue by Type (2027-2032) & (US$ Million) Table 147. SAMEA Human Microbiome Revenue by Application (2021-2026) & (US$ Million) Table 148. SAMEA Human Microbiome Revenue by Application (2027-2032) & (US$ Million) Table 149. SAMEA Human Microbiome Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. SAMEA Human Microbiome Revenue by Country (2021-2026) & (US$ Million) Table 151. SAMEA Human Microbiome Revenue by Country (US$ Million) & (2027-2032) Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Human Microbiome Image Figure 2. Global Human Microbiome Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Microbiome Market Size Share 2021 VS 2025 VS 2032 Figure 4. Gastrointestinal Tract Human Micobiome Image Figure 5. Urogenital Tract Human Micobiome Image Figure 6. Others Image Figure 7. Global Human Microbiome Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Human Microbiome Market Size Share 2021 VS 2025 VS 2032 Figure 9. Treatment Image Figure 10. Diagnosis Image Figure 11. Global Human Microbiome Market Size (US$ Million) & (2021-2032) Figure 12. Global Human Microbiome Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Human Microbiome Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Human Microbiome Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Human Microbiome Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Human Microbiome Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Human Microbiome Revenue Market Share by Type (2021-2032) Figure 19. Global Human Microbiome Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Human Microbiome Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Human Microbiome Revenue Market Share by Application (2021-2032) Figure 22. North America Human Microbiome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Human Microbiome Revenue Share by Type (2021-2032) Figure 24. North America Human Microbiome Revenue Share by Application (2021-2032) Figure 25. North America Human Microbiome Revenue Share by Country (2021-2032) Figure 26. United States Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Human Microbiome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Human Microbiome Revenue Share by Type (2021-2032) Figure 31. Europe Human Microbiome Revenue Share by Application (2021-2032) Figure 32. Europe Human Microbiome Revenue Share by Country (2021-2032) Figure 33. Germany Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Human Microbiome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Human Microbiome Revenue Share by Type (2021-2032) Figure 43. China Human Microbiome Revenue Share by Application (2021-2032) Figure 44. Asia Human Microbiome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Human Microbiome Revenue Share by Type (2021-2032) Figure 46. Asia Human Microbiome Revenue Share by Application (2021-2032) Figure 47. Asia Human Microbiome Revenue Share by Region (2021-2032) Figure 48. Japan Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Human Microbiome Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Human Microbiome Revenue Share by Type (2021-2032) Figure 56. SAMEA Human Microbiome Revenue Share by Application (2021-2032) Figure 57. SAMEA Human Microbiome Revenue Share by Country (2021-2032) Figure 58. Brazil Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Human Microbiome Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Gastrointestinal Tract Human Micobiome
  • Urogenital Tract Human Micobiome
  • Others
Applications
  • Treatment
  • Diagnosis
Companies covered
  • Vedanta
  • Seres Therapeutics
  • Second Genome
  • Rebiotix
  • ActoGeniX
  • Enterome BioScience
  • AvidBiotics
  • 4D Pharma Research Ltd
  • Enterologics
  • Metabogen
  • Metabiomics
  • Ritter Pharmaceuticals
  • Osel
  • Symberix
  • Miomics
  • Symbiotix Biotherapies
  • MicroBiome Therapeutics LLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Human Microbiome Market by Type
  3. 1.2.1 Global Human Microbiome Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Gastrointestinal Tract Human Micobiome
  5. 1.2.3 Urogenital Tract Human Micobiome
  6. 1.2.4 Others
  7. 1.3 Human Microbiome Market by Application
  8. 1.3.1 Global Human Microbiome Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Treatment
  10. 1.3.3 Diagnosis
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Human Microbiome Market Dynamics
  1. 2.1 Human Microbiome Industry Trends
  2. 2.2 Human Microbiome Industry Drivers
  3. 2.3 Human Microbiome Industry Opportunities and Challenges
  4. 2.4 Human Microbiome Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Human Microbiome Market Perspective (2021-2032)
  2. 3.2 Global Human Microbiome Growth Trends by Region
  3. 3.2.1 Global Human Microbiome Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Human Microbiome Market Size by Region (2021-2026)
  5. 3.2.3 Global Human Microbiome Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Human Microbiome Revenue by Players
  2. 4.1.1 Global Human Microbiome Revenue by Players (2021-2026)
  3. 4.1.2 Global Human Microbiome Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Human Microbiome Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Human Microbiome Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Human Microbiome Key Players Headquarters & Area Served
  7. 4.4 Global Human Microbiome Players, Product Type & Application
  8. 4.5 Global Human Microbiome Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Human Microbiome Market CR5 and HHI
  11. 4.6.3 2025 Human Microbiome Tier 1, Tier 2, and Tier 3
5 Human Microbiome Market Size by Type
  1. 5.1 Global Human Microbiome Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Human Microbiome Revenue by Type (2021-2032)
  3. 5.3 Global Human Microbiome Revenue Market Share by Type (2021-2032)
6 Human Microbiome Market Size by Application
  1. 6.1 Global Human Microbiome Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Human Microbiome Revenue by Application (2021-2032)
  3. 6.3 Global Human Microbiome Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Vedanta
  2. 7.1.1 Vedanta Company Information
  3. 7.1.2 Vedanta Business Overview
  4. 7.1.3 Vedanta Human Microbiome Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Vedanta Human Microbiome Product Portfolio
  6. 7.1.5 Vedanta Recent Developments
  7. 7.2 Seres Therapeutics
  8. 7.2.1 Seres Therapeutics Company Information
  9. 7.2.2 Seres Therapeutics Business Overview
  10. 7.2.3 Seres Therapeutics Human Microbiome Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Seres Therapeutics Human Microbiome Product Portfolio
  12. 7.2.5 Seres Therapeutics Recent Developments
  13. 7.3 Second Genome
  14. 7.3.1 Second Genome Company Information
  15. 7.3.2 Second Genome Business Overview
  16. 7.3.3 Second Genome Human Microbiome Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Second Genome Human Microbiome Product Portfolio
  18. 7.3.5 Second Genome Recent Developments
  19. 7.4 Rebiotix
  20. 7.4.1 Rebiotix Company Information
  21. 7.4.2 Rebiotix Business Overview
  22. 7.4.3 Rebiotix Human Microbiome Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Rebiotix Human Microbiome Product Portfolio
  24. 7.4.5 Rebiotix Recent Developments
  25. 7.5 ActoGeniX
  26. 7.5.1 ActoGeniX Company Information
  27. 7.5.2 ActoGeniX Business Overview
  28. 7.5.3 ActoGeniX Human Microbiome Revenue and Gross Margin (2021-2026)
  29. 7.5.4 ActoGeniX Human Microbiome Product Portfolio
  30. 7.5.5 ActoGeniX Recent Developments
  31. 7.6 Enterome BioScience
  32. 7.6.1 Enterome BioScience Company Information
  33. 7.6.2 Enterome BioScience Business Overview
  34. 7.6.3 Enterome BioScience Human Microbiome Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Enterome BioScience Human Microbiome Product Portfolio
  36. 7.6.5 Enterome BioScience Recent Developments
  37. 7.7 AvidBiotics
  38. 7.7.1 AvidBiotics Company Information
  39. 7.7.2 AvidBiotics Business Overview
  40. 7.7.3 AvidBiotics Human Microbiome Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AvidBiotics Human Microbiome Product Portfolio
  42. 7.7.5 AvidBiotics Recent Developments
  43. 7.8 4D Pharma Research Ltd
  44. 7.8.1 4D Pharma Research Ltd Company Information
  45. 7.8.2 4D Pharma Research Ltd Business Overview
  46. 7.8.3 4D Pharma Research Ltd Human Microbiome Revenue and Gross Margin (2021-2026)
  47. 7.8.4 4D Pharma Research Ltd Human Microbiome Product Portfolio
  48. 7.8.5 4D Pharma Research Ltd Recent Developments
  49. 7.9 Enterologics
  50. 7.9.1 Enterologics Company Information
  51. 7.9.2 Enterologics Business Overview
  52. 7.9.3 Enterologics Human Microbiome Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Enterologics Human Microbiome Product Portfolio
  54. 7.9.5 Enterologics Recent Developments
  55. 7.10 Metabogen
  56. 7.10.1 Metabogen Company Information
  57. 7.10.2 Metabogen Business Overview
  58. 7.10.3 Metabogen Human Microbiome Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Metabogen Human Microbiome Product Portfolio
  60. 7.10.5 Metabogen Recent Developments
  61. 7.11 Metabiomics
  62. 7.11.1 Metabiomics Company Information
  63. 7.11.2 Metabiomics Business Overview
  64. 7.11.3 Metabiomics Human Microbiome Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Metabiomics Human Microbiome Product Portfolio
  66. 7.11.5 Metabiomics Recent Developments
  67. 7.12 Ritter Pharmaceuticals
  68. 7.12.1 Ritter Pharmaceuticals Company Information
  69. 7.12.2 Ritter Pharmaceuticals Business Overview
  70. 7.12.3 Ritter Pharmaceuticals Human Microbiome Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Ritter Pharmaceuticals Human Microbiome Product Portfolio
  72. 7.12.5 Ritter Pharmaceuticals Recent Developments
  73. 7.13 Osel
  74. 7.13.1 Osel Company Information
  75. 7.13.2 Osel Business Overview
  76. 7.13.3 Osel Human Microbiome Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Osel Human Microbiome Product Portfolio
  78. 7.13.5 Osel Recent Developments
  79. 7.14 Symberix
  80. 7.14.1 Symberix Company Information
  81. 7.14.2 Symberix Business Overview
  82. 7.14.3 Symberix Human Microbiome Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Symberix Human Microbiome Product Portfolio
  84. 7.14.5 Symberix Recent Developments
  85. 7.15 Miomics
  86. 7.15.1 Miomics Company Information
  87. 7.15.2 Miomics Business Overview
  88. 7.15.3 Miomics Human Microbiome Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Miomics Human Microbiome Product Portfolio
  90. 7.15.5 Miomics Recent Developments
  91. 7.16 Symbiotix Biotherapies
  92. 7.16.1 Symbiotix Biotherapies Company Information
  93. 7.16.2 Symbiotix Biotherapies Business Overview
  94. 7.16.3 Symbiotix Biotherapies Human Microbiome Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Symbiotix Biotherapies Human Microbiome Product Portfolio
  96. 7.16.5 Symbiotix Biotherapies Recent Developments
  97. 7.17 MicroBiome Therapeutics LLC
  98. 7.17.1 MicroBiome Therapeutics LLC Company Information
  99. 7.17.2 MicroBiome Therapeutics LLC Business Overview
  100. 7.17.3 MicroBiome Therapeutics LLC Human Microbiome Revenue and Gross Margin (2021-2026)
  101. 7.17.4 MicroBiome Therapeutics LLC Human Microbiome Product Portfolio
  102. 7.17.5 MicroBiome Therapeutics LLC Recent Developments
8 North America
  1. 8.1 North America Human Microbiome Revenue (2021-2032)
  2. 8.2 North America Human Microbiome Revenue by Type (2021-2032)
  3. 8.2.1 North America Human Microbiome Revenue by Type (2021-2026)
  4. 8.2.2 North America Human Microbiome Revenue by Type (2027-2032)
  5. 8.3 North America Human Microbiome Revenue Share by Type (2021-2032)
  6. 8.4 North America Human Microbiome Revenue by Application (2021-2032)
  7. 8.4.1 North America Human Microbiome Revenue by Application (2021-2026)
  8. 8.4.2 North America Human Microbiome Revenue by Application (2027-2032)
  9. 8.5 North America Human Microbiome Revenue Share by Application (2021-2032)
  10. 8.6 North America Human Microbiome Revenue by Country
  11. 8.6.1 North America Human Microbiome Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Human Microbiome Revenue by Country (2021-2026)
  13. 8.6.3 North America Human Microbiome Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Human Microbiome Revenue (2021-2032)
  2. 9.2 Europe Human Microbiome Revenue by Type (2021-2032)
  3. 9.2.1 Europe Human Microbiome Revenue by Type (2021-2026)
  4. 9.2.2 Europe Human Microbiome Revenue by Type (2027-2032)
  5. 9.3 Europe Human Microbiome Revenue Share by Type (2021-2032)
  6. 9.4 Europe Human Microbiome Revenue by Application (2021-2032)
  7. 9.4.1 Europe Human Microbiome Revenue by Application (2021-2026)
  8. 9.4.2 Europe Human Microbiome Revenue by Application (2027-2032)
  9. 9.5 Europe Human Microbiome Revenue Share by Application (2021-2032)
  10. 9.6 Europe Human Microbiome Revenue by Country
  11. 9.6.1 Europe Human Microbiome Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Human Microbiome Revenue by Country (2021-2026)
  13. 9.6.3 Europe Human Microbiome Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Human Microbiome Revenue (2021-2032)
  2. 10.2 China Human Microbiome Revenue by Type (2021-2032)
  3. 10.2.1 China Human Microbiome Revenue by Type (2021-2026)
  4. 10.2.2 China Human Microbiome Revenue by Type (2027-2032)
  5. 10.3 China Human Microbiome Revenue Share by Type (2021-2032)
  6. 10.4 China Human Microbiome Revenue by Application (2021-2032)
  7. 10.4.1 China Human Microbiome Revenue by Application (2021-2026)
  8. 10.4.2 China Human Microbiome Revenue by Application (2027-2032)
  9. 10.5 China Human Microbiome Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Human Microbiome Revenue (2021-2032)
  2. 11.2 Asia Human Microbiome Revenue by Type (2021-2032)
  3. 11.2.1 Asia Human Microbiome Revenue by Type (2021-2026)
  4. 11.2.2 Asia Human Microbiome Revenue by Type (2027-2032)
  5. 11.3 Asia Human Microbiome Revenue Share by Type (2021-2032)
  6. 11.4 Asia Human Microbiome Revenue by Application (2021-2032)
  7. 11.4.1 Asia Human Microbiome Revenue by Application (2021-2026)
  8. 11.4.2 Asia Human Microbiome Revenue by Application (2027-2032)
  9. 11.5 Asia Human Microbiome Revenue Share by Application (2021-2032)
  10. 11.6 Asia Human Microbiome Revenue by Country
  11. 11.6.1 Asia Human Microbiome Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Human Microbiome Revenue by Country (2021-2026)
  13. 11.6.3 Asia Human Microbiome Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Human Microbiome Revenue (2021-2032)
  2. 12.2 SAMEA Human Microbiome Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Human Microbiome Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Human Microbiome Revenue by Type (2027-2032)
  5. 12.3 SAMEA Human Microbiome Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Human Microbiome Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Human Microbiome Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Human Microbiome Revenue by Application (2027-2032)
  9. 12.5 SAMEA Human Microbiome Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Human Microbiome Revenue by Country
  11. 12.6.1 SAMEA Human Microbiome Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Human Microbiome Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Human Microbiome Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst